Tuesday, May 30, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Laboratories Team Up to Develop BSL 4 Level Screening Platform

by Global Biodefense Staff
May 4, 2012

Southern Research Institute and the University of Texas Medical Branch (UTMB) at Galveston will collaborate to develop and validate a high-volume, high-throughput screening (HTS) platform in the Galveston National Laboratory (GNL) Biosafety Level 4 (BSL-4) laboratory. The partnership will provide the opportunity for disease screening in the highest level of biocontainment facility, in an effort to seek out new therapeutics in the fight against pathogens that create public health and biodefense threats.

GNL operates one of two National Biocontainment Laboratories constructed under grants awarded by the National Institute of Allergy and Infectious Diseases (NIAID). The facility is certified to work with some of the most contagious and dangerous pathogens on the planet in the pursuit of developing therapies, vaccines and diagnostic tests for bioterror agents or highly pathogenic infectious diseases.

Southern Research has extensive experience in platform and assay development for HTS formats, currently conducted at their own BSL-3 laboratories. The organization first developed its BSL-3 HTS platform over seven years ago in response the SARS outbreak and the federal government’s request to increase screening and drug discovery in infectious diseases. Since then, Southern Research has successfully conducted thousands of compound screening campaigns in BSL-3 high containment.

The HTS experience of Southern Research combined with the unique resources of GNL provide a great outlook for the partnership. Researchers at both institutions will benefit from the collaborative effort to facilitate and enhance screening for candidate compounds that are effective against highly-pathogenic viruses.

“Being able to exploit high-throughput screening options against diseases like Ebola and Nipah viruses in a BSL-4 lab in an academic setting is quite a unique opportunity,” said Dr. Thomas G. Ksiazek, GNL Director of High Containment Operations.

Tags: BiosafetyEbolaNipah Virus

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC